Efficacy and Tolerability after Unusually Low Doses of Dasatinib in Chronic Myeloid Leukemia Patients Intolerant to Standard-Dose Dasatinib Therapy

• Main Authors: Mariana Serpa, Sabri S. Sanabani, Israel Bendit, Fernanda Seguro, Flávia Xavier, Cláudia Bitti Barroso, Monika Conchon, Pedro Enrique Dorlhiac-Llacer
• Format: Article
• Language: English
• Published: SAGE Publishing 2010-01-01
• Series: Clinical Medicine Insights: Oncology
• Online Access: https://doi.org/10.4137/CMO.S6413

We report our experience in 4 patients with chronic myeloid leukemia (CML) who had discontinued imatinib as a result of adverse events and had switched to dasatinib. The chronic phase ( n 2) and accelerated phase ( n 2) CML patients received dasatinib at starting dose of 100 and 140 mg once daily, respectively. Reappearance of hematological toxicity was observed in 3 patients and pancreatitis in one patient. Treatment was given at a lower dose and patients were followed. The median follow-up was 13 months and the median dose of dasatinib until achievement of complete cytogenetic remission (CCyR) was 60 mg daily (range = 20 to 120 mg). All four patients had achieved CCyR at a median of 4 months (range = 3 to 5 months) and among them, three had also achieved major molecular remission. We conclude that low-dose dasatinib therapy in intolerant patients appears safe and efficacious and may be tried before drug discontinuation.